ET
CRL icon

Equitable Trust’s Charles River Laboratories CRL Stock Holding History

Equitable Trust’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,423
Closed -$447K – 465
2024
Q4 		$447K Hold
2,423
– – 0.03% 340
2024
Q3 		$477K Sell
2,423
-43
-2% -$8.94K 0.03% 324
2024
Q2 		$509K Hold
2,466
– – 0.04% 293
2024
Q1 		$668K Buy
2,466
+184
+8% +$43.9K 0.05% 249
2023
Q4 		$539K Buy
2,282
+576
+34% +$113K 0.04% 267
2023
Q3 		$334K Hold
1,706
– – 0.03% 324
2023
Q2 		$359K Sell
1,706
-229
-12% -$45.6K 0.03% 314
2023
Q1 		$391K Sell
1,935
-213
-10% -$48.3K 0.03% 297
2022
Q4 		$468K Buy
+2,148
New +$469K 0.04% 272

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Equitable Trust's CRL Position: Q1 2025 in Review

Equitable Trust sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 2,423 shares — an estimated $447K sold.

Equitable Trust first reported a position in CRL in Q4 2022 and held it in 9 quarters. The position peaked at $668K in Q1 2024. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

  • Equitable Trust reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
  • Equitable Trust sold 2,423 Charles River Laboratories shares in Q1 2025, an estimated $447K.
  • Equitable Trust first reported a position in Charles River Laboratories in Q4 2022 and held it in 9 quarters.
  • Equitable Trust's Charles River Laboratories position peaked at $668K in Q1 2024.
  • 561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on Equitable Trust's 13F filing for Q1 2025, filed 25 Apr 2025.